Recent Investment Analysts’ Ratings Changes for Masimo (MASI)

Masimo (NASDAQ: MASI) has recently received a number of price target changes and ratings updates:

• 5/7/2025 – Masimo was given a new $193.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.
• 5/7/2025 – Masimo had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $200.00 price target on the stock, down previously from $215.00.
• 5/7/2025 – Masimo had its price target lowered by analysts at Wells Fargo & Company from $205.00 to $190.00. They now have an “overweight” rating on the stock.
• 5/7/2025 – Masimo had its price target lowered by analysts at Raymond James from $204.00 to $185.00. They now have an “outperform” rating on the stock.
• 4/10/2025 – Masimo had its “hold” rating reaffirmed by analysts at Needham & Company LLC.

Masimo Stock Performance

Shares of MASI opened at $163.56 on Tuesday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $8.87 billion, a price-to-earnings ratio of 112.80 and a beta of 1.23. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $194.88. The company’s fifty day moving average is $161.21 and its 200-day moving average is $167.10.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.12. The company had revenue of $372.00 million for the quarter, compared to the consensus estimate of $367.79 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm’s revenue was down 24.5% compared to the same quarter last year. During the same period last year, the business posted $0.77 earnings per share. Equities analysts expect that Masimo Co. will post 4.1 EPS for the current fiscal year.

Insider Buying and Selling at Masimo

In related news, Director Craig B. Reynolds sold 2,053 shares of the firm’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the transaction, the director now owns 16,581 shares in the company, valued at $2,754,601.53. This trade represents a 11.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares in the company, valued at $4,048,568.28. This represents a 55.38% decrease in their position. The disclosure for this sale can be found here. Insiders own 9.70% of the company’s stock.

Institutional Trading of Masimo

Large investors have recently added to or reduced their stakes in the company. Nuveen LLC acquired a new position in Masimo during the 1st quarter worth about $25,830,000. Aigen Investment Management LP acquired a new position in shares of Masimo during the 1st quarter worth about $271,000. Entropy Technologies LP bought a new stake in Masimo in the first quarter valued at approximately $300,000. Townsquare Capital LLC increased its position in shares of Masimo by 21.5% in the 1st quarter. Townsquare Capital LLC now owns 9,870 shares of the medical equipment provider’s stock valued at $1,644,000 after buying an additional 1,744 shares in the last quarter. Finally, NS Partners Ltd raised its position in shares of Masimo by 2.1% during the first quarter. NS Partners Ltd now owns 43,555 shares of the medical equipment provider’s stock worth $7,256,000 after purchasing an additional 906 shares during the period. 85.96% of the stock is owned by institutional investors.

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.